In Trial 201, we investigated the efficacy and safety of treatment with naxitamab plus GM-CSF in patients with R/R HR neuroblastoma with residual disease limited to the bone and/or BM, a well-defined segment of the overall HR neuroblastoma population in urgent need of efficacious treatment options with manageable safety profiles. The gene discussed is CSF2; the disease is neuroblastoma.